Why Gilead’s $5bn Tubulis deal could reshape its solid tumour pipeline strategy
Gilead’s Tubulis deal strengthens its ADC pipeline, but oncology execution, safety and clinical proof now decide the upside.
Pharma & Biotech
Pharma & Biotech
ASCO 2026: Tubulis set to present maturing Phase I/IIa data on TUB-040 exatecan ADC in PROC
Tubulis presents updated TUB-040 Phase I/IIa data at ASCO 2026. Here is what the NAPISTAR 1-01 readout means for NaPi2b and ovarian cancer treatment.
Pharma & Biotech
Why Tubulis gives Gilead more than just another antibody-drug conjugate asset
Gilead is acquiring Tubulis to expand its antibody-drug conjugate pipeline. Read what the deal changes for oncology strategy and ADC competition.